Illumina, Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? Illumina, Inc. trades at $190.04 (market cap $27.94B), while ABRDN Physical Gold Shares ETF trades at $38.78. The key difference: Illumina, Inc. is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | SGOL | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $194.33 | $51.41 |
52-Week Low | $91.00 | $31.18 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
SGOL is trading at $38.16, down 0.16% with a bearish technical outlook indicated by 16 sell signals against 0 buy signals. The stock faces pressure from higher interest rate expectations and dollar strength, though central bank gold buying provides structural support. Recent trading has tested key support levels around $38 with resistance forming at $39.
The outlook remains cautious with technical indicators signaling bearish momentum and fundamental data limited. Investment opportunities exist for long-term gold exposure, but risks include Fed policy uncertainty and dollar volatility. Near-term direction depends on gold's ability to hold $4,000/oz support amid competing macroeconomic forces.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →